Lymphoplasmacytic Lymphoma Associated with Diffuse Large B-cell Lymphoma: Progression or Divergent Evolution?

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2020 Nov 12

PMID 33180881

Citations 4

Authors

Macarena Boiza-Sanchez

Rebeca Manso

Olga Balague

Cristina Chamizo

Elham Askari

Rocio Nieves Salgado

Carlos Blas-Lopez

Elena Aguirregoicoa-Garcia

Javier Menarguez

Carlos Santonja

Magdalena Adrados

Miguel Angel Limeres-Gonzalez

Miguel Angel Piris

Socorro Maria Rodriguez-Pinilla

Affiliations

Soon will be listed here.

Abstract

Aim: Lymphoplasmacytic lymphoma (LPL) is an indolent mature B-cell-neoplasm with involvement of the bone marrow. At least 90% of LPLs carry MYD88-L265P mutation and some of them (~10%) transform into diffuse large B-cell-lymphoma (DLBCL).

Material And Methods: Over the past 15 years we have collected 7 cases where the both LPL and DLBCL were diagnosed in the same patient. Clinical records, analytical data and histopathological specimens were reviewed. FISH studies on paraffin-embedded tissue for MYC, BCL2 and BCL6 genes were performed, as well as MYD88-L265P mutation and IGH rearrangement analysis by PCR. A mutational study was done by massive next generation sequencing (NGS).

Results: There were 4 women and 3 men between 36-91 years of age. Diagnoses were made simultaneously in 4 patients. In two cases the LPL appeared before the DLBCL and in the remaining case the high-grade component was discovered 5 years before the LPL. In 6 cases both samples shared the MYD88-L265P mutation. IGH rearrangement analysis showed overlapping features in two of 6 cases tested. Mutational study was evaluable in three cases for both samples showing shared and divergent mutations.

Conclusions: These data suggest different mechanisms of DLBCL development in LPL patients.

Citing Articles

Central nervous system involvement in Waldenström macroglobulinemia: a comparative population-based study of Bing-Neel syndrome and histological transformation.

Ostergaard S, Munksgaard L, Hammer T, Nielsen T, Pedersen M, Gjerdrum L Ann Hematol. 2025; .

PMID: 39853347 DOI: 10.1007/s00277-025-06194-4.

MYD88 mutation-positive indolent B-cell lymphoma with CNS involvement: Bing-Neel syndrome mimickers.

Takeda K, Okazaki S, Minami R, Ichiki A, Yamaga Y, Nakajima K J Clin Exp Hematop. 2024; 64(3):252-260.

PMID: 39218689 PMC: 11528247. DOI: 10.3960/jslrt.24033.

In-depth molecular analysis of lymphomas with lymphoplasmacytic differentiation may provide more precise diagnosis and rational treatment allocation.

Brunner A, Thalhammer-Thurner G, Willenbacher W, Haun M, Zelger B, Willenbacher E Ann Hematol. 2023; 103(2):553-563.

PMID: 37951851 PMC: 10798918. DOI: 10.1007/s00277-023-05531-9.

Clonal Relationship and Mutation Analysis in Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia Associated With Diffuse Large B-cell Lymphoma.

Berendsen M, van Bladel D, Hesius E, Berganza Irusquieta C, Rijntjes J, Spriel A Hemasphere. 2023; 7(11):e976.

PMID: 37928625 PMC: 10621888. DOI: 10.1097/HS9.0000000000000976.

Hemophagocytic lymphohistiocytosis as an onset of diffuse large B-cell lymphoma: A case report.

Cao Y, Zou L, Zhou H, Fu G, Zhao X Oncol Lett. 2022; 24(3):298.

PMID: 35949601 PMC: 9353227. DOI: 10.3892/ol.2022.13418.

References

Rosenquist R, Rosenwald A, Du M, Gaidano G, Groenen P, Wotherspoon A . Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond. Haematologica. 2016; 101(9):1002-9. PMC: 5060016. DOI: 10.3324/haematol.2015.134510. View

Fukumura K, Kawazu M, Kojima S, Ueno T, Sai E, Soda M . Genomic characterization of primary central nervous system lymphoma. Acta Neuropathol. 2016; 131(6):865-75. DOI: 10.1007/s00401-016-1536-2. View

Treon S, Tripsas C, Meid K, Warren D, Varma G, Green R . Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med. 2015; 372(15):1430-40. DOI: 10.1056/NEJMoa1501548. View

Franco F, Gonzalez-Rincon J, Lavernia J, Garcia J, Martin P, Bellas C . Mutational profile of primary breast diffuse large B-cell lymphoma. Oncotarget. 2017; 8(61):102888-102897. PMC: 5732697. DOI: 10.18632/oncotarget.21986. View

Treon S, Xu L, Hunter Z . MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia. N Engl J Med. 2015; 373(6):584-6. DOI: 10.1056/NEJMc1506192. View

Ciric B, VanKeulen V, Rodriguez M, Kyle R, Gertz M, Pease L . Clonal evolution in Waldenstrom macroglobulinemia highlights functional role of B-cell receptor. Blood. 2001; 97(1):321-3. DOI: 10.1182/blood.v97.1.321. View

Shimizu S, Tamagawa Y, Kojima H, Mori N, Nagata M, Noguchi M . Simultaneous development of lymphoplasmacytic lymphoma and diffuse large B-cell lymphoma--analyses of the clonal relatedness by sequencing CDR3 in immunoglobulin heavy chain genes. Eur J Haematol. 2003; 70(2):119-24. DOI: 10.1034/j.1600-0609.2003.00013.x. View

Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-405. DOI: 10.1182/blood-2016-03-643544. View

Xu L, Tsakmaklis N, Yang G, Chen J, Liu X, Demos M . Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia. Blood. 2017; 129(18):2519-2525. PMC: 7484977. DOI: 10.1182/blood-2017-01-761726. View

10.

Talaulikar D, Biscoe A, Lim J, Gibson J, Arthur C, Mackinlay N . Genetic analysis of Diffuse Large B-cell Lymphoma occurring in cases with antecedent Waldenström Macroglobulinaemia reveals different patterns of clonal evolution. Br J Haematol. 2018; 185(4):767-770. DOI: 10.1111/bjh.15610. View

11.

Morton L, Sampson J, Cerhan J, Turner J, Vajdic C, Wang S . Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014; 2014(48):1-14. PMC: 4155460. DOI: 10.1093/jncimonographs/lgu005. View

12.

Varettoni M, Zibellini S, Defrancesco I, Ferretti V, Rizzo E, Malcovati L . Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. Haematologica. 2017; 102(12):2077-2085. PMC: 5709107. DOI: 10.3324/haematol.2017.172718. View

13.

Durot E, Tomowiak C, Michallet A, Dupuis J, Hivert B, Lepretre S . Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO). Br J Haematol. 2017; 179(3):439-448. DOI: 10.1111/bjh.14881. View

14.

Hattori K, Sakata-Yanagimoto M, Kusakabe M, Nanmoku T, Suehara Y, Matsuoka R . Genetic evidence implies that primary and relapsed tumors arise from common precursor cells in primary central nervous system lymphoma. Cancer Sci. 2018; 110(1):401-407. PMC: 6317941. DOI: 10.1111/cas.13848. View

15.

Vater I, Montesinos-Rongen M, Schlesner M, Haake A, Purschke F, Sprute R . The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing. Leukemia. 2014; 29(3):677-85. DOI: 10.1038/leu.2014.264. View

16.

Vermaat J, Somers S, de Wreede L, Kraan W, de Groen R, Schrader A . mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis. Haematologica. 2019; 105(2):424-434. PMC: 7012469. DOI: 10.3324/haematol.2018.214122. View

17.

Schmitz R, Wright G, Huang D, Johnson C, Phelan J, Wang J . Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018; 378(15):1396-1407. PMC: 6010183. DOI: 10.1056/NEJMoa1801445. View

18.

Zanwar S, Abeykoon J, Durot E, King R, Perez Burbano G, Kumar S . Impact of MYD88 mutation status on histological transformation of Waldenström Macroglobulinemia. Am J Hematol. 2019; 95(3):274-281. DOI: 10.1002/ajh.25697. View

19.

Treon S, Xu L, Liu X, Hunter Z, Yang G, Castillo J . Genomic Landscape of Waldenström Macroglobulinemia. Hematol Oncol Clin North Am. 2018; 32(5):745-752. DOI: 10.1016/j.hoc.2018.05.003. View

20.

Yu X, Li W, Deng Q, Li L, Hsi E, Young K . L265P Mutation in Lymphoid Malignancies. Cancer Res. 2018; 78(10):2457-2462. DOI: 10.1158/0008-5472.CAN-18-0215. View